Statement Of Cash Flows [Abstract]

Mithra Pharmaceuticals S.A. - Filing #3183195

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	116 875 EUR	116 875 EUR	92 086 EUR	—	92 086 EUR	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories	—	8 470 EUR	—	—	—	19 105 EUR	—
Adjustments for share-based payments	—	1 065 EUR	—	—	—	7 267 EUR	—
Cash flows from (used in) operating activities	—	74 387 EUR	—	—	—	80 025 EUR	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	- EUR	—	—	—	23,000 EUR	—
Purchase of property, plant and equipment, classified as investing activities	—	11 483 EUR	—	—	—	10 645 EUR	—
Purchase of intangible assets, classified as investing activities	—	9 699 EUR	—	—	—	5 585 EUR	—
Cash flows from (used in) investing activities	—	54 682 EUR	—	—	—	16 207 EUR	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	9 213 EUR	—	—	—	65,731,000 EUR	—
Payments of lease liabilities, classified as financing activities	—	7 193 EUR	—	—	—	3 475 EUR	—
Proceeds from government grants, classified as financing activities	—	41,000 EUR	—	—	—	5 835 EUR	—
Interest paid, classified as financing activities	—	11 765 EUR	—	—	—	3 503 EUR	—
Cash flows from (used in) financing activities	—	23 245 EUR	—	—	—	185 187 EUR	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	21,000 EUR	—	—	—	- EUR	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	105 824 EUR	—	—	—	88 954 EUR	—
Cash and cash equivalents	32,872,000 EUR	—	—	—	138,675,000 EUR	—	49,720,000 EUR